ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $1.03B invested in Adaptimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.2% less ownership
Funds ownership: 14.19% → 13.99% (-0.2%)
20% less capital invested
Capital invested by funds: $1.28B → $1.03B (-$254M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
79
Holding in Top 10
2
Calls
$2.02M
Puts
$1.04M
Top Buyers
| 1 | +$14.3M | |
| 2 | +$13.6M | |
| 3 | +$8.03M | |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$7.98M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$6.78M |
Top Sellers
| 1 | -$13.7M | |
| 2 | -$11.7M | |
| 3 | -$7.83M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.77M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.12M |